IDWeek

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

At IDWeek 2026, clinicians explained how the meeting breaks down silos and keeps them ahead of what's next in infectious disease care.

Senu Apewokin, MD, explains why asymptomatic C diff carriage complicates care for transplant and chemotherapy patients excluded from trials.

Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling help.

Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure.

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

Jordan Feld, MD, MPH, explains how HBsAg testing, NUC therapy, and monitoring capacity will shape access to hepatitis B functional cure.

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis C cases.

Aditi Ramakrishnan, MD, MSc, explains how pharmacy benefit gaps and prior authorization denials keep patients from long-acting injectable PrEP.

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

The US has curative HCV treatment and rapid tests but lags peer nations in prevention for people who inject drugs.

Naima T. Joseph, MD, MPH, explains measles risks in pregnancy, atypical presentations, and the narrow window for prophylaxis.

Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.

Universal HCV testing in pregnancy, DAA therapy, and earlier infant RNA testing can curb mother-to-child hepatitis C transmission.

Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.

Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.

Immediate DAA treatment, syringe services, and society advocacy are key to eliminating the hepatitis C virus (HCV) among people who use drugs.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.